Elrexfio 40 mg/mL injection Images
Generic Name: elranatamab
This medication has been identified as Elrexfio 40 mg/mL injection. It is supplied by Pfizer Inc.
Elrexfio is used in the treatment of Multiple Myeloma and belongs to the drug class bispecific T-cell engagers (BiTE). Elrexfio 40 mg/mL injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Elrexfio
- Generic Name
- elranatamab
- Strength
- 40 mg/mL injection
- Availability
- Prescription only
- Drug Class
- Bispecific T-cell engagers (BiTE)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Pfizer Inc.
- National Drug Code (NDC)
See also:
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
More about Elrexfio (elranatamab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.